Colorectal Cancer
Conditions
Keywords
circulating tumor DNA, recurrence
Brief summary
This observational study aims to assess the predictive value of postoperative circulating tumor DNA (ctDNA) monitoring in evaluating the risk of recurrence in stage I-IV colorectal cancer patients. The study involves the collection of blood samples from patients who have undergone surgery for colorectal cancer. Sensitivity-enhanced molecular biology techniques are utilized to detect ctDNA in these samples. The correlation between ctDNA detection and the risk of recurrence is evaluated by analyzing patient follow-up data and clinical information. The findings of this study may contribute to the development of improved postoperative management strategies, such as identifying high-risk individuals and implementing additional treatment measures to reduce the risk of recurrence.
Interventions
OTHERSerial ctDNA monitoring
Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
Sponsors
Guangzhou Burning Rock Dx Co., Ltd.
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years at the time of signing the informed consent form. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1. 3. Histologically confirmed colorectal cancer located from the ileocecal junction to the rectosigmoid junction, with a distance of \>15cm from the anal verge. Regardless of mismatch repair (MMR) status, Rat sarcoma (RAS) gene and proto-oncogene serine/threonine-protein kinase (RAF) gene status. 4. Pathologically or cytologically confirmed American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) stage I-IV colorectal cancer patients (8th edition). 5. No evidence of distant metastasis confirmed by comprehensive examination (no distant organ or lymph node metastasis). 6. Normal organ function, as indicated by the following criteria: * Hematology criteria: For patients who have not received blood transfusion, white blood cell (WBC) ≥ 3.5/4.0 × 10\^9/L, neutrophils ≥ 1.5 × 10\^9/L, platelet (PLT) ≥ 100 × 10\^9/L. * Biochemistry criteria: Crea and bilirubin (BIL) ≤ 1.0 times the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN, alkaline phosphatase (ALP) ≤ 2.5 × ULN, total bilirubin (Tbil) ≤ 1.5 × ULN. 7. Ability to provide clinical data required for the study. 8. Sufficient tumor tissue available for analysis. 9. Patients capable of achieving R0 radical resection. 10. Patients capable of adhering to the planned schedule, actively participating in regular clinical follow-up, and necessary treatments.
Exclusion criteria
1. History of concurrent or prior malignancies (excluding adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin). 2. Patients who have received neoadjuvant therapy. 3. Patients with other severe diseases that may affect follow-up and short-term survival, as determined by the investigator. 4. Any other medical, social, or psychological conditions that, in the opinion of the investigator, would make the patient unsuitable for participation in this study. 5. Inability to undergo clinical follow-up using contrast-enhanced magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year recurrence free survival rate of the cohort evaluated by ctDNA | 2 years post surgery | To evaluate the correlation between circulating tumor DNA (ctDNA) detection and recurrence-free survival. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The ctDNA positive rate in stage III colorectal cancer | Within 4-6 week post operation | To assess positive rate of ctDNA minimal residual disease (MRD) test in stage III of colorectal cancer patient after surgery. |
| Time point of ctDNA MRD test for recurrence monitoring | Within 4-6 week post operation | To assess time from positive ctDNA test to clinical recurrence. |
Countries
China
Outcome results
None listed